Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2)

BMC Medicine

Patrick J Sinko¹  Eric Rubin¹  Viral Vyas¹  Sung-Hack Lee²  Pankaj V Paranjpe²  Ailan Guo³  Feng R Luo⁴  Anita K Lalloo² 

[1] The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA;Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA;Hoffmann-La Roche, Department of Discovery Pharmacology, Nutley, New Jersey, USA;Bristol Myers Squibb Co., Princeton, New Jersey, USA

关键词: secretion;    P-glycoprotein;    membrane transport;    Multidrug Resistance Protein 2;    MDCK II cells;    efflux;    camptothecin;    Caco-2 cells;   

Others  :  1130703
DOI  :  10.1186/1741-7015-2-16

 received in 2003-12-02, accepted in 2004-05-04,  发布年份 2004

【 摘 要 】

Background

The purpose of the present study was to continue the investigation of the membrane transport mechanisms of 20-(S)-camptothecin (CPT) in order to understand the possible role of membrane transporters on its oral bioavailability and disposition.

Methods

The intestinal transport kinetics of CPT were characterized using Caco-2 cells, MDCKII wild-type cells and MDCKII cells transfected with human P-glycoprotein (PGP) (ABCB1) or human multidrug resistance protein 2 (MRP2) (ABCC2). The effects of drug concentration, inhibitors and temperature on CPT directional permeability were determined.

Results

The absorptive (apical to basolateral) and secretory (basolateral to apical) permeabilities of CPT were found to be saturable. Reduced secretory CPT permeabilities with decreasing temperatures suggests the involvement of an active, transporter-mediated secretory pathway. In the presence of etoposide, the CPT secretory permeability decreased 25.6%. However, inhibition was greater in the presence of PGP and of the breast cancer resistant protein inhibitor, GF120918 (52.5%). The involvement of additional secretory transporters was suggested since the basolateral to apical permeability of CPT was not further reduced in the presence of increasing concentrations of GF120918. To investigate the involvement of specific apically-located secretory membrane transporters, CPT transport studies were conducted using MDCKII/PGP cells and MDCKII/MRP2 cells. CPT carrier-mediated permeability was approximately twofold greater in MDCKII/PGP cells and MDCKII/MRP2 cells than in MDCKII/wild-type cells, while the apparent K_m values were comparable in all three cell lines. The efflux ratio of CPT in MDCKII/PGP in the presence of 0.2 μM GF120918 was not completely reversed (3.36 to 1.49). However, the decrease in the efflux ratio of CPT in MDCKII/MRP2 cells (2.31 to 1.03) suggests that CPT efflux was completely inhibited by MK571, a potent inhibitor of the Multidrug Resistance Protein transporter family.

Conclusions

The current results provide evidence that PGP and MRP2 mediate the secretory transport of CPT in vitro. However, the involvement of other transporters cannot be ruled out based on these studies. Since these transporters are expressed in the intestine, liver and kidney variations in their expression levels and/or regulation may be responsible for the erratic oral absorption and biliary excretion of CPT observed in human subjects.

【 授权许可】

   
2004 Lalloo et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Wang JC: DNA topoisomerases. Annu Rev Biochem 1985, 54:665-697.
• [2]Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970, 54:461-470.
• [3]Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD: Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989, 32:715-720.
• [4]Hsiang YH, Hertzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260:14873-14878.
• [5]Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I – targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246:1046-1048.
• [6]Del Bino G, Lassota P, Darzynkiewicz Z: The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991, 193:27-35.
• [7]Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J: Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998, 4:1153-1158.
• [8]Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36:393-403.
• [9]Gupta E, Vyas V, Ahmed F, Sinko P, Cook T, Rubin E: Pharmacokinetics of orally administered camptothecins. Ann NY Acad Sci 2000, 922:195-204.
• [10]Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML: Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999, 17:685-696.
• [11]Schellens JH, Creemers GJ, Beijnen JH, Rosing H, Boer-Dennert M, McDonald M, Davies B, Verweij J: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996, 73:1268-1271.
• [12]Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998, 9:36-44.
• [13]Scott DO, Bindra DS, Sutton SC, Stella VJ: Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 1994, 22:438-442.
• [14]Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JH: Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 1998, 77:1645-1652.
• [15]Yang CJ, Horton JK, Cowan KH, Schneider E: Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 1995, 55:4004-4009.
• [16]Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko PJ, Rubin EH: Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 2003, 63:3228-3233.
• [17]Williams GC, Liu A, Knipp G, Sinko PJ: Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002, 46:3456-3462.
• [18]Liang E, Proudfoot J, Yazdanian M: Mechanisms of transport and structure–permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 2000, 17:1168-1174.
• [19]Gupta E, Luo F, Lallo A, Ramanathan S, Vyas V, Rubin E, Sinko P: The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s). Anticancer Res 2000, 20:1013-1016.
• [20]Hidalgo IJ, Borchardt RT: Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim Biophys Acta 1990, 1028:25-30.
• [21]Hyafil F, Vergely C, Du P, Grand-Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918 an acridonecarboxamide derivative. Cancer Res 1993, 53:4595-4602.
• [22]Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ: Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998, 15:1160-1167.
• [23]Chu XY, Kato Y, Sugiyama Y: Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab Dispos 1999, 27:440-441.
• [24]Sugiyama Y, Kato Y, Chu X: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998, 42(Suppl):S44-S49.
• [25]Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 1996, 36:161-183.
• [26]Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992, 52:2268-2278.
• [27]Jansen WJ, Hulscher TM, Ark-Otte J, Giaccone G, Pinedo HM, Boven E: CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 1998, 77:359-365.
• [28]Vanhoefer U, Muller MR, Hilger RA, Lindtner B, Klaassen U, Schleucher N, Rustum YM, Seeber S, Harstrick A: Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer 1999, 81:1304-1310.
• [29]Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991, 51:6039-6044.
• [30]Hoki Y, Fujimori A, Pommier Y: Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 1997, 40:433-438.
• [31]Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK: In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993, 5:467-474.
• [32]Mouly S, Paine MF: P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003, 20:1595-1599.